您的位置: 专家智库 > 作者详情>马微微

文献类型

  • 2篇中文期刊文章

领域

  • 2篇医药卫生

主题

  • 1篇蛋白
  • 1篇试剂
  • 1篇试剂盒
  • 1篇肿瘤
  • 1篇肿瘤标志
  • 1篇肿瘤标志物
  • 1篇硫氧还蛋白
  • 1篇硫氧还蛋白还...
  • 1篇检测试剂
  • 1篇检测试剂盒
  • 1篇恶性
  • 1篇恶性肿瘤
  • 1篇CELLS
  • 1篇GEMCIT...
  • 1篇JF305
  • 1篇MIAPAC...
  • 1篇标志物
  • 1篇VIABIL...

机构

  • 2篇北京大学
  • 1篇湖北中医药大...
  • 1篇天津国际生物...

作者

  • 2篇马微微
  • 2篇曾慧慧
  • 1篇熊堃
  • 1篇罗钰
  • 1篇赵友云
  • 1篇回艺

传媒

  • 1篇Journa...
  • 1篇国际检验医学...

年份

  • 1篇2013
  • 1篇2012
2 条 记 录,以下是 1-2
排序方式:
Wbselen and gemcitabine synergistically inhibited the viability of JF305 and MiaPaCa-2 human pancreatic cancer cells
2013年
Gemcitabine (GEM) is a cell-cycle specific inhibitor of DNA synthesis and repair, and has been applied as the first-line therapy for patients with locally advanced or metastatic pancreatic cancers. However, the median survival time is only 5.65 mon when GEM was administrated as a monothearpy. Therefore, novel therapeutic agents and/or combinations with GEM are needed for the treatment of pancreatic cancer. In this study, we aim to evaluate the efficacy of treatment with wbselen (WB), GEM, and combination treatment with GEM and WB in two pancreatic cancer cell lines, JF305 and MiaPaCa-2 cells. The combination index (CI) and the dose-reduction index (DRI) of combined treatment with different dose and time regimes were analyzed based on median-effect theory. Compared with single treatment with GEM, combination treatment displayed decreased response time and IC 50 , and increased maximum inhibition. Among the different combination regimes, the most significant synergistic effect was achieved when the dose ratios of WB to GEM was 2:1 in JF305 cells and 1:1 in MiaPaCa-2 cells after 48 h of drug treatment. When combinations of WB and GEM were used in these two cell lines, the dose of GEM was significantly reduced while the total drug concentration increased, especially after 48 h of drug treatments. Our results indicated that the combination treatment with WB and GEM had synergistic effect against pancreatic cancer in vitro.
回艺马微微熊堃曾慧慧
硫氧还蛋白还原酶活性检测试剂盒在恶性肿瘤辅助诊断中的价值被引量:11
2012年
目的探讨硫氧还蛋白还原酶(TR)活性检测试剂盒在恶性肿瘤辅助诊断中的价值。方法检测不同地区、不同检验机构1122例健康人群TR活性,差异有无统计学意义;检测84例恶性肿瘤患者TR活性,并与健康人群比较,差异有无统计学意义,通过ROC曲线对检测结果进行分析评价。结果北京体检机构的TR活性均值为(2.6±4.1)U/mL,武汉体检机构的TR均值为(2.6±3.7)U/mL,湖北中医药大学附属医院的TR均值为(2.4±3.5)U/mL,各组间TR活性水平差异无统计学意义(P>0.05);肿瘤组TR活性均值为(9.2±6.4)U/mL,健康组TR活性为(2.5±3.7)U/mL,两者间差异有统计学意义(P<0.05)。固定健康组和肿瘤组的样本比例为4:1,不同的样本量间TR活性差异无统计学意义(P>0.05)。ROC曲线下面积为0.812±0.029。结论组间均数比较U检验和ROC曲线评价均显示,TR活性检测试剂盒用于与异常增生密切相关的肿瘤生长的临床血样检测具有重要的实用价值。
罗钰马微微杨晶吴琳李月琴赵友云曾慧慧
关键词:肿瘤标志物硫氧还蛋白还原酶
共1页<1>
聚类工具0